KBI Biopharma, Inc., a JSR Life Sciences company, launched SUREmAb, an offering built on KBI’s SUREtechnology Platform designed for optimized, safe, and cost-efficient monoclonal antibody (mAb) development and manufacturing.
SUREmAb is a vertically integrated global offering designed to minimize development timelines for global biopharmaceutical manufacturers, delivering research cell bank (RCB) development in as little as nine weeks and the ability for customers to move from DNA to GMP drug substance in as few as 11 months, according to the company. In addition, SUREmAb is engineered to achieve titers of up to 10 g/L with a lower-cost workflow to optimize operational efficiency and maximize ROI.
According to the company, the operational consolidation of KBI Biopharma and Selexis, played an important role in the operations that power the SUREmAb technology, enabling KBI to streamline processes and offer greater efficiencies in monoclonal antibody development and manufacturing.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!